Lupin launches Posaconazole Delayed-Release Tablets

Lupin launches Posaconazole Delayed-Release Tablets

Picture: Pixabay

Lupin announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma US (part of Tiefenbacher Group) received approval for its ANDA from the United States Food and Drug Administration (USFDA)

Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil Delayed Release Tablets, 100 mg, of Merck Sharp & Dohme Corp,.

These tablets are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Posaconazole Delayed-Release Tablets, 100 mg (RLD: Noxafil) had estimated annual sales of $186 million in the US (IQVIA MAT December 2020).

Also read:

Glenmark launches Kidney drug at 96% lower price

Lupin, Aurobindo units recall medicines in US market

Alembic gets USFDA final nod for Treprostinil injection

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates